Science Problem · Mine for Science

🔋 Mine Multiple Sclerosis Research — Earn SXOR

👥
People Affected

2,800,000 people impacted by this problem

🧩
Total Chunks

600,000 computation chunks to solve

🌐
Mine Free

Browser mining — no downloads or hardware needed

💰
Earn SXOR

Every solved chunk earns SXOR directly to your wallet

About This Research Problem

MS causes the immune system to attack myelin — the insulating sheath around nerve fibers — producing progressive disability. Current treatments slow the immune attack but don't repair existing damage. Distributed simulation models oligodendrocyte precursor cell behavior under different molecular conditions, identifying the signals that trigger natural remyelination. If these signals can be pharmacologically activated, damaged myelin could regenerate in MS patients. Supported by MS Society Research and Cambridge Neuroscience.

How to Start Mining

1
Create Account

Free signup — 60 seconds

2
Select Problem

Choose this problem from the dashboard dropdown

3
Click Start

Mining begins immediately in your browser

Start mining multiple sclerosis research now.

⚡ Create Free Account

Already have an account? Sign in →

Other Science Problems

🧬
Cancer Research

Contribute your computer's idle power to pancreatic cancer protein mapping.

💧
Clean Water

Help detect waterborne pathogens through distributed computing.

🌍
Climate Change

Run carbon capture optimization models in your browser.

🌬️
Air Pollution

Help trace sources of air pollution through distributed computing.

🕊️
Peace Conflict

Contribute to conflict pattern modeling research.

🧠
Parkinsons Disease

Contribute to Parkinson's disease alpha-synuclein protein mapping.

Als Disease

Contribute to ALS / Lou Gehrig's disease research.

🫁
Lung Cancer

Lung cancer kills 1.

🧬
Alzheimers Disease

55 million people have Alzheimer's disease — the number doubles every 20 years.

🌱
Childhood Leukemia

Pediatric ALL has 90% survival in wealthy countries — but resistance kills thousands annually.

💨
Cystic Fibrosis

CFTR modulators transformed CF for 90% of patients — but 10% have rare mutations with no approved therapy.